Organovo (ONVO) announced the close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (LLY). The transaction was completed on March 25. With the closing ...

Lilly is acquiring all commercial and intellectual property rights to Organovo’s FXR program for worldwide development and will be responsible for all future clinical development. About Organovo ...